Current Report Filing (8-k)
May 16 2022 - 5:05PM
Edgar (US Regulatory)
0001349929
false
0001349929
2022-05-16
2022-05-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): May 16, 2022
VYANT
BIO, INC.
(Exact
Name of Company as Specified in its Charter)
Delaware |
|
001-35817 |
|
04-3462475 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
2
Executive Campus
2370
State Route 70, Suite 310
Cherry
Hill, NJ 08002
(Address
of Principal Executive Offices) (Zip Code)
Company’s
telephone number, including area code (201) 479-8126
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any
of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the Company is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock |
|
VYNT |
|
The
Nasdaq Capital Market |
Item
8.01. Other Events.
On
May 16, 2022, Vyant Bio, Inc. (the “Registrant”) used the slides attached hereto as Exhibit 99.1 in connection with management
presentations to describe its business. Exhibit 99.1 hereto is incorporated by reference herein.
Forward-Looking
Statements
This
report, including Exhibit 99.1 furnished herewith, contains forward-looking statements within the meaning of the federal securities laws.
Forward-looking statements typically are identified by use of terms such as “may,” “will,” “should,”
“plan,” “expect,” “anticipate,” “estimate” and similar words, and the opposites of such
words, although some forward-looking statements are expressed differently. Forward-looking statements involve known and unknown risks
and uncertainties that exist in the Registrant’s operations and business environment, which may be beyond the Registrant’s
control, and which may cause actual results, performance or achievements to be materially different from future results, performance
or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are
statements that could be forward- looking statements. For example, forward-looking statements include, without limitation: statements
pertaining to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, the efficacy of our drug screening
and discovery process, potential for our services, future revenues or growth and plans, strategies and objectives of management for future
operations or transactions. The risks and uncertainties referred to above include, but are not limited to, risks detailed from time to
time in the Registrant’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the
year ended December 31, 2021 and any subsequent filings. These risks could cause actual results to differ materially from those expressed
in any forward-looking statements made by, or on behalf of, the Registrant. Forward-looking statements represent the judgment of management
of the Registrant regarding future events. Although the Registrant believes that the expectations reflected in such forward-looking statements
are reasonable at the time that they are made, the Registrant can give no assurance that such expectations will prove to be correct.
Unless otherwise required by applicable law, the Registrant assumes no obligation to update any forward-looking statements, and expressly
disclaims any obligation to do so, whether as a result of new information, future events or otherwise.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
As
described above, the following exhibits are furnished as part of this report:
Exhibit
99.1 - |
|
Presentation. |
Exhibit
104 - |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
VYANT
BIO, INC. |
|
|
|
|
|
|
By: |
/s/
John A. Roberts |
|
|
Name: |
John
A. Roberts |
|
|
Title: |
President
and Chief Executive Officer |
|
|
|
|
Date: |
May
16, 2022 |
|
|
Vyant Bio (NASDAQ:VYNT)
Historical Stock Chart
From Apr 2024 to May 2024
Vyant Bio (NASDAQ:VYNT)
Historical Stock Chart
From May 2023 to May 2024